Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991851 | 0.81 | NPC1 (0.42) | EPHB3JAK1TYK2NPC1RAB9A | |
| SCHEMBL11303602 | 0.79 | CDK2 (0.53) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| SCHEMBL1160390 | 0.79 | CDK2 (0.49) | CDK2EPHB3JAK1TYK2NPC1 | |
| SCHEMBL25776610 | 0.79 | CDK2 (0.49) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| SCHEMBL12875621 | 0.79 | CDK2 (0.41) | CDK2EPHB3MAP2K1TSHRKMT2A | |
| SCHEMBL1160399 | 0.79 | CDK2 (0.49) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| SCHEMBL14017228 | 0.78 | CDK2 (0.45) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| Hydrochloric Acid SCHEMBL29483244 | 0.78 | CDK2 (0.51) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| Hydrochloric Acid SCHEMBL29516534 | 0.78 | CDK2 (0.51) | CDK2EPHB3JAK1TYK2MAP2K1 | |
| Bromide SCHEMBL29769300 | 0.78 | CDK2 (0.51) | CDK2EPHB3JAK1TYK2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125803-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| EP-3102570-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-9586969-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432373-B2 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | CDK2 423/4885EPHB3 3982/4885JAK1 1/4885 |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | CDK2 2678/4885EPHB3 1336/4885JAK1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.